We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Showcases Cutting-Edge Innovations in Diagnostics

By LabMedica International staff writers
Posted on 04 Feb 2025

Beckman Coulter Diagnostics (Brea, CA, USA) is displaying its comprehensive range of analyzers and solutions at Medlab Middle East 2025. More...

The company is demonstrating how it is advancing healthcare through innovation and supporting laboratories to deliver consistent, reliable, and fast results.

At the 2025 edition of Medlab Middle East, Beckman Coulter is showcasing the DxC 500i integrated clinical chemistry and immunoassay analyzer that incorporates DxC 500 AU chemistry analyzer technology with Six Sigma performance. Utilizing Beckman Coulter’s common reagents and consumables across its scalable clinical chemistry and immunoassay portfolio, the DxC 500i Analyzer enables commutable patient results, offering hospitals and healthcare networks strategic benefits in patient care and inventory management. The DxC 500i Clinical Analyzer features FlexMode operations, prioritizing immunoassay and chemistry testing according to each sample's urgency. The new dynamic sample handler manages repeats and re-runs without operator intervention and pulls in a new sample rack as soon as the previous rack is offloaded, optimizing rapid throughput in a compact footprint. Of equal importance, the DxC 500i’s intuitive interface supports even the newest users through proactive task indicators, step-by-step instructions and simplified staff onboarding and training.

Beckman Coulter is also highlighting the award-winning DxI 9000 immunoassay analyzer which sets a new standard with first-of-its-kind high-sensitivity immunoassay testing capabilities for the core labs. Featuring meaningful innovations, this high-throughput immunoassay analyzer takes diagnostics to the next level. Its novel, patented machine vision technology utilizes multiple cameras with defined algorithms to detect and notify users of processing errors in real time, triggering course correction right away. In addition to advancing diagnostics capabilities, the DxI 9000 excels in improving clinical laboratory operations. ZeroDaily Maintenance highlights the embedded innovations that drive the DxI 9000 Analyzer’s uptime performance. Beta users attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Portable POCT Blood Gas Analyzer
BD100
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.